Skip to main content

Investor Relations

Harnessing Immune Synergy

Next-Gen T Cell Therapies for Cancer

We are an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Our proprietary approach to T cell engineering integrates desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, designed to engage the body's full immune repertoire for optimized cancer therapy. Our novel cellular immunotherapy platform, which redirects patient-derived T cells to eliminate tumors by employing phagocytic mechanisms, creates Chimeric Engulfment Receptor T cells (“CER-T”). We believe CER-T cells will offer greater therapeutic application than currently approved chimeric antigen receptor (“CAR”) T cell therapies, spanning both hematological malignancies and solid tumors.

CERo's Vision

Transforming Cancer Treatment through Genetic Engineering

CERo, incorporated in Delaware on September 23, 2016, and based in South San Francisco, focuses on genetically engineering immune cells to fight cancer. Since inception, CERo has developed its therapeutic platform but has not started clinical trials or product commercialization. Future efforts will aim at clinical development and regulatory approval. The company has significant operating losses, with a net loss of $7.3 million for 2023, an accumulated deficit of $43.1 million, and $1.6 million in cash. CERo expects continued net losses and rising R&D and administrative expenses.

Latest News

Sign up for email alerts

Stay connected and get the latest company news delivered to your inbox.

Contacts

Corporate Headquarters

201 Haskins Way, Suite 230
South San Francisco, California 94080
(215) 731-9450
info@cero.bio
Investors: investors@cero.bio